{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:15:00Z","timestamp":1793060100417,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21-AI173475"],"award-info":[{"award-number":["R21-AI173475"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24-AI185302"],"award-info":[{"award-number":["K24-AI185302"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-AI052071"],"award-info":[{"award-number":["T32-AI052071"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011576","name":"Johns Hopkins\u2019 Physician Scientist Training","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011576","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to characterize susceptibility profiles of both currently approved and investigational \u03b2-lactam agents against difficult-to-treat resistant Pseudomonas aeruginosa (DTR P. aeruginosa) clinical isolates, including carbapenemase-producing strains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>A total of 502 consecutive DTR P. aeruginosa clinical isolates were collected from unique hospitalized patients between 2022 and 2024 across three tertiary care centres. Isolates originated from bloodstream, respiratory, urinary and intra-abdominal infections. Minimum inhibitory concentrations (MICs) for seven \u03b2-lactam agents were determined using triplicate reference broth microdilution. Susceptibility interpretations were based on CLSI criteria or, where applicable, investigational breakpoints. Whole-genome sequencing was performed to detect \u03b2-lactamase genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 502 isolates, cefepime-zidebactam exhibited the highest in vitro activity (100% susceptibility), followed by cefiderocol-xeruborbactam (98%), cefiderocol (95%), ceftolozane-tazobactam (90%), cefepime-taniborbactam (86%), ceftazidime-avibactam (85%), and imipenem-relebactam (41%). Notably, only 35% of isolates were susceptible to all seven agents. Carbapenemase genes were identified in 4% of isolates, including blaGES (n\u200a=\u200a13), blaVIM (n\u200a=\u200a7), blaKPC (n\u200a=\u200a1) and blaIMP (n\u200a=\u200a1). Among carbapenemase-producing isolates, cefepime-zidebactam retained activity against all isolates (100%), exceeding that of other approved \u03b2-lactam\/\u03b2-lactamase inhibitor combinations (0%\u201324% susceptible), cefiderocol (76%), cefiderocol-xeruborbactam (86%) and cefepime-taniborbactam (81%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While currently approved \u03b2-lactam agents retained activity against many DTR P. aeruginosa isolates, their performance was markedly compromised in the presence of carbapenemases, with the notable exceptions of cefepime-zidebactam and cefiderocol. Investigational \u03b2-lactam\/\u03b2-lactamase inhibitor combinations exhibited consistently robust activity across resistance phenotypes, including carbapenemase-producing isolates, representing promising options for DTR P. aeruginosa infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag138","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:31:44Z","timestamp":1784205104000},"source":"Crossref","is-referenced-by-count":3,"title":["Comparative evaluation of the activity of novel \u03b2-lactam antibiotics against difficult-to-treat\n                    <i>Pseudomonas aeruginosa<\/i>\n                    clinical isolates"],"prefix":"10.1093","volume":"8","author":[{"given":"Harry","family":"Mystakelis","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-5665","authenticated-orcid":false,"given":"Ryan K","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J","family":"Mathers","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Virginia , Charlottesville, VA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4262-7173","authenticated-orcid":false,"given":"Yehudit","family":"Bergman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-1056","authenticated-orcid":false,"given":"Jose M","family":"Munita","sequence":"additional","affiliation":[{"name":"Facultad de Medicina Cl\u00ednica Alemana, Universidad del Desarrollo, Instituto de Ciencias e Innovaci\u00f3n en Medicina , Santiago ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-4331","authenticated-orcid":false,"given":"Sara E","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J","family":"Simner","sequence":"additional","affiliation":[{"name":"Department of Pathology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4143-6324","authenticated-orcid":false,"given":"Pranita D","family":"Tamma","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"2026071608313843900_dlag138-B1","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","article-title":"Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study","volume":"4","author":"Reyes","year":"2023","journal-title":"Lancet Microbe"},{"key":"2026071608313843900_dlag138-B2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01759-19","article-title":"Predictors of mortality in bloodstream infections caused by Pseudomonas aeruginosa and impact of antimicrobial resistance and bacterial virulence","volume":"64","author":"Recio","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071608313843900_dlag138-B3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cmi.2023.12.026","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID\/ISARPAE group","volume":"30","author":"Oliver","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026071608313843900_dlag138-B4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026071608313843900_dlag138-B5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.idc.2025.11.001","article-title":"Current management strategies of difficult-to-treat resistant Pseudomonas aeruginosa infections","volume":"40","author":"Horcajada","year":"2026","journal-title":"Infect Dis Clin North Am"},{"key":"2026071608313843900_dlag138-B6","author":"CLSI"},{"key":"2026071608313843900_dlag138-B7","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/jac\/dkad098","article-title":"Assessing the in vivo efficacy of rational antibiotics and combinations against difficult-to-treat Pseudomonas aeruginosa producing GES beta-lactamases","volume":"78","author":"Abouelhassan","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026071608313843900_dlag138-B8","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/jac\/dkz571","article-title":"Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013\u201317","volume":"75","author":"Kazmierczak","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026071608313843900_dlag138-B9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1128\/AAC.02379-15","article-title":"Multiyear, multinational survey of the incidence and global distribution of metallo-beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa","volume":"60","author":"Kazmierczak","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071608313843900_dlag138-B10","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/jac\/dkz030","article-title":"High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial","volume":"74","author":"Perez","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026071608313843900_dlag138-B11","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10096-018-3244-4","article-title":"Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data","volume":"37","author":"Karampatakis","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026071608313843900_dlag138-B12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/cid\/ciae052","article-title":"Extensively drug-resistant Pseudomonas aeruginosa outbreak associated with artificial tears","volume":"79","author":"Grossman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026071608313843900_dlag138-B13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1021\/bi501052t","article-title":"Kinetic and structural requirements for carbapenemase activity in GES-type beta-lactamases","volume":"54","author":"Stewart","year":"2015","journal-title":"Biochemistry"},{"key":"2026071608313843900_dlag138-B14","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00991-23","article-title":"Relative inhibitory activities of the broad-spectrum beta-lactamase inhibitor taniborbactam against metallo-beta-lactamases","volume":"68","author":"Le Terrier","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071608313843900_dlag138-B15","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/jac\/dkaa036","article-title":"Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa","volume":"75","author":"Moya","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026071608313843900_dlag138-B16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00552-20","article-title":"Impact of intrinsic resistance mechanisms on potency of QPX7728, a new ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases in Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii","volume":"64","author":"Lomovskaya","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071608313843900_dlag138-B17","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf252","article-title":"Activity of novel antibiotics against dual metallo-beta-lactamase producing Enterobacter hormaechei clinical isolates","volume":"8","author":"Solar","year":"2026","journal-title":"JAC Antimicrob Resist"},{"key":"2026071608313843900_dlag138-B18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026071608313843900_dlag138-B19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026071608313843900_dlag138-B20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S1473-3099(25)00469-4","article-title":"Cefiderocol versus standard therapy for hospital-acquired and health-care-associated gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial","volume":"26","author":"Paterson","year":"2026","journal-title":"Lancet Infect Dis"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag138\/69025617\/dlag138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag138\/69025617\/dlag138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:31:45Z","timestamp":1784205105000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag138\/8735797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag138","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"dlag138"}}